<SEC-DOCUMENT>0001415889-24-015360.txt : 20240604
<SEC-HEADER>0001415889-24-015360.hdr.sgml : 20240604
<ACCEPTANCE-DATETIME>20240604163009
ACCESSION NUMBER:		0001415889-24-015360
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240601
FILED AS OF DATE:		20240604
DATE AS OF CHANGE:		20240604

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			SCHIFF ANDREW N
		CENTRAL INDEX KEY:			0001172252
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37581
		FILM NUMBER:		241018587

	MAIL ADDRESS:	
		STREET 1:		PLANET ZANETT INC
		STREET 2:		135 E 57TH ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER NAME:	
		FORMER CONFORMED NAME:	SCHIFF DR DREW
		DATE OF NAME CHANGE:	20020426

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aclaris Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001557746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				460571712
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		484-324-7933

	MAIL ADDRESS:	
		STREET 1:		701 LEE ROAD
		STREET 2:		SUITE 103
		CITY:			WAYNE
		STATE:			PA
		ZIP:			19087
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-06042024_040604.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-01</periodOfReport>

    <issuer>
        <issuerCik>0001557746</issuerCik>
        <issuerName>Aclaris Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ACRS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001172252</rptOwnerCik>
            <rptOwnerName>SCHIFF ANDREW N</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ACLARIS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>701 LEE ROAD, SUITE 103</rptOwnerStreet2>
            <rptOwnerCity>WAYNE</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>19087</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-06-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4660</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9167</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>434455</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Aisling Capital IV LP</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Stock Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-06-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>4660</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>4660</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.</footnote>
        <footnote id="F2">The reportable securities are owned directly by Aisling Capital IV, LP (&quot;Aisling&quot;), and held indirectly by Aisling Capital Partners IV, LP (&quot;Aisling GP&quot;), as general partner of Aisling, Aisling Capital Partners IV LLC (&quot;Aisling Partners&quot;), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the &quot;Managers&quot;) of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.</footnote>
        <footnote id="F3">The shares underlying these restricted stock units vested on June 1, 2024.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Matthew Rothman, Attorney-in-Fact</signatureName>
        <signatureDate>2024-06-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24-06042024_040606.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex24-06042024_040606.htm</title><meta name="author" content="Stefanie Duffy"><meta name="date" content="05/16/2024"></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px" align="center"><b>POWER OF ATTORNEY</b></p>
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="center">(For Executing Form ID and Forms 3, 4 and 5)</p>
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px; text-indent:61.067px" align="justify">Know all by these presents, that the undersigned hereby constitutes and appoints each of Kevin Balthaser and Matthew Rothman of Aclaris Therapeutics, Inc. (the &#147;<b><i>Company</i></b>&#148;) and Mark Ballantyne, David Brinton and Robin Lee of Cooley LLP, the undersigned&#146;s true and lawful attorneys-in-fact and agents to:</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:61.067px; width:122.133px; float:left">(1)</p>
<p style="margin:0px; text-indent:-2px" align="justify">Prepare, execute in the undersigned&#146;s name and on the undersigned&#146;s behalf, and submit to the Securities and Exchange Commission (the &#147;<b><i>SEC</i></b>&#148;) a Form ID, Uniform Application for Access Codes to File on EDGAR, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#147;<b><i>Exchange Act</i></b>&#148;), or any rule or regulation thereunder;</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:61.067px; width:122.133px; float:left">(2)</p>
<p style="margin:0px; text-indent:-2px" align="justify">Prepare, execute in the undersigned&#146;s name and on the undersigned&#146;s behalf, and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Exchange Act and the rules thereunder in the undersigned&#146;s capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:61.067px; width:122.133px; float:left">(3)</p>
<p style="margin:0px; text-indent:-2px" align="justify">Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:61.067px; width:122.133px; float:left">(4)</p>
<p style="margin:0px; text-indent:-2px" align="justify">Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact&#146;s discretion.</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; text-indent:61.067px" align="justify">The undersigned hereby grants to each such ttorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact&#146;s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. &nbsp;The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned&#146;s responsibilities to comply with Section 16 of the Exchange Act.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:61.067px" align="justify">This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned&#146;s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP, as applicable. </p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:61.067px" align="justify">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:60px; float:left">Date: </p>
<p style="margin:0px; text-indent:-2px" align="justify"><u>05/16/2024</u></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; text-indent:60px" align="justify"><u>/s/ Andrew Schiff</u></p>
<p style="margin:0px; text-indent:60px; font-size:6pt" align="justify">ANDREW SCHIFF</p>
<p style="margin:0px" align="justify"><br><br><br><br><br><br></p>
<p style="line-height:10pt; margin:0px; font-family:Verdana,Times New Roman; font-size:9pt">&nbsp;</p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
